196 related articles for article (PubMed ID: 30504401)
1. Prognostic Significance of 14-3-3ε, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Wu CY; Jan YJ; Ko BS; Wu YJ; Wu YJ; Liou JY
Anticancer Res; 2018 Dec; 38(12):6855-6863. PubMed ID: 30504401
[TBL] [Abstract][Full Text] [Related]
2. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma.
Liu TA; Jan YJ; Ko BS; Wu YJ; Lu YJ; Liang SM; Liu CC; Chen SC; Wang J; Shyue SK; Liou JY
Oncotarget; 2015 Nov; 6(36):38967-82. PubMed ID: 26516929
[TBL] [Abstract][Full Text] [Related]
3. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Sato S; Genda T; Ichida T; Murata A; Tsuzura H; Narita Y; Kanemitsu Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
J Gastroenterol Hepatol; 2016 Jul; 31(7):1315-22. PubMed ID: 26758591
[TBL] [Abstract][Full Text] [Related]
4. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
6. Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Sato S; Genda T; Hirano K; Tsuzura H; Narita Y; Kanemitsu Y; Kikuchi T; Iijima K; Wada R; Ichida T
Liver Int; 2012 Oct; 32(9):1382-90. PubMed ID: 22681639
[TBL] [Abstract][Full Text] [Related]
7. High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Ha SY; Song DH; Lee JJ; Lee HW; Cho SY; Park CK
Gut Liver; 2014 Nov; 8(6):648-54. PubMed ID: 25287169
[TBL] [Abstract][Full Text] [Related]
8. ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma.
Wu YJ; Ko BS; Liang SM; Lu YJ; Jan YJ; Jiang SS; Shyue SK; Chen L; Liou JY
Cell Death Dis; 2019 May; 10(6):408. PubMed ID: 31138789
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Murata A; Genda T; Ichida T; Amano N; Sato S; Tsuzura H; Sato S; Narita Y; Kanemitsu Y; Shimada Y; Hirano K; Iijima K; Wada R; Nagahara A; Watanabe S
World J Gastroenterol; 2016 Sep; 22(33):7569-78. PubMed ID: 27672277
[TBL] [Abstract][Full Text] [Related]
10. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
11. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
Ko BS; Jan YJ; Chang TC; Liang SM; Chen SC; Liu TA; Wu YM; Wang J; Liou JY
Anticancer Agents Med Chem; 2013 May; 13(4):555-62. PubMed ID: 22934705
[TBL] [Abstract][Full Text] [Related]
13. 14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma.
Liu TA; Jan YJ; Ko BS; Liang SM; Chen SC; Wang J; Hsu C; Wu YM; Liou JY
PLoS One; 2013; 8(3):e57968. PubMed ID: 23483955
[TBL] [Abstract][Full Text] [Related]
14. Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.
Matkowskyj KA; Bai H; Liao J; Zhang W; Li H; Rao S; Omary R; Yang GY
Hum Pathol; 2014 Apr; 45(4):834-43. PubMed ID: 24656094
[TBL] [Abstract][Full Text] [Related]
15. Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Tsuzura H; Genda T; Sato S; Murata A; Kanemitsu Y; Narita Y; Ishikawa S; Kikuchi T; Mori M; Hirano K; Iijima K; Wada R; Ichida T
Int J Mol Sci; 2014 Apr; 15(4):6556-68. PubMed ID: 24747592
[TBL] [Abstract][Full Text] [Related]
16. AKR1B10 expression characteristics in hepatocellular carcinoma and its correlation with clinicopathological features and immune microenvironment.
Ma LN; Ma Y; Luo X; Ma ZM; Ma LN; Ding XC
Sci Rep; 2024 May; 14(1):12149. PubMed ID: 38802416
[TBL] [Abstract][Full Text] [Related]
17. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Wang YY; Qi LN; Zhong JH; Qin HG; Ye JZ; Lu SD; Ma L; Xiang BD; Li LQ; You XM
Sci Rep; 2017 Feb; 7():42199. PubMed ID: 28181486
[TBL] [Abstract][Full Text] [Related]
18. IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma.
Cheng BY; Lau EY; Leung HW; Leung CO; Ho NP; Gurung S; Cheng LK; Lin CH; Lo RC; Ma S; Ng IO; Lee TK
Cancer Res; 2018 May; 78(9):2332-2342. PubMed ID: 29483095
[TBL] [Abstract][Full Text] [Related]
19. Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Kanno M; Kawaguchi K; Honda M; Horii R; Takatori H; Shimakami T; Kitamura K; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol; 2019 Jun; 54(6):549-557. PubMed ID: 30707282
[TBL] [Abstract][Full Text] [Related]
20. Expression of metallothionein-1 and metallothionein-2 as a prognostic marker in hepatocellular carcinoma.
Park Y; Yu E
J Gastroenterol Hepatol; 2013 Sep; 28(9):1565-72. PubMed ID: 23662831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
